BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Beacon Endoscopic Announces Spin-Off Business for Incisionless Digestive Bypass Technology


9/13/2012 7:05:11 AM

NEWTON, MA--(Marketwire - September 13, 2012) - Beacon Endoscopic Corporation, an emerging GI endoscopy company, announced today a spin-off business, GI Windows, that will develop and bring to market a technology involving a series of self-assembling magnets (SAMSEN) for incisionless bypass procedures within the digestive system.

Two years ago, professors and physicians at Massachusetts Institute of Technology and Brigham & Women's Hospital licensed the SAMSEN platform to Beacon Endoscopic for development in collaboration with the inventors.

"This novel, endoluminally-delivered device offers interventional endoscopists and surgeons the ability to create a leak-free connection between hollow organs without an incision," says Peter Lukin, Vice President, Operations at Beacon Endoscopic. "The continuous compression of the self-assembling magnets stops blood supply at the targeted area and leads to cell necrosis, allowing the body to use its own healing power to form an anastomosis between the adjacent structures."

Dr. Christopher Thompson, Co-Founder of GI Windows and Assistant Professor of Medicine at Harvard University, states, "The incisionless platform holds the potential to change the way we treat Type II diabetes and obesity. Our minimally invasive endoscopic approach will allow these procedures to be performed efficiently under conscious sedation, and avoid the need for permanent implants. This will be a more cost-effective approach than surgery or the current standard of long-term medication. It may very well change the paradigm of care for these patients."

To date, pre-clinical studies have been spearheaded by Marvin Ryou, MD of Brigham & Women's Hospital and most recently presented at Digestive Disease Week 2012 in San Diego, CA.

The Board of Directors of GI Windows includes Brian Tinkham, Peter Rogal and Christopher Thompson, who also serve on the Beacon Endoscopic Board of Directors. They will be actively seeking strategic investors in early 2013 to help bring this revolutionary technology to the medical community.

About Beacon Endoscopic
Beacon Endoscopic is dedicated to innovating medical devices in interventional endoscopy procedures. Our mission is to develop high quality medical devices, designed to minimize healthcare costs, accelerate procedural efficiency, promote safety and provide superior clinical outcomes for patients.


For further information, contact:
Brian Tinkham
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES